Anticoagulant treatment in stroke prevention

Related Experiment Video

Updated: Oct 18, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

P J Koudstaal1

  • 1Department of Neurology, University Hospital Rotterdam, The Netherlands.

Revue Neurologique
|October 21, 1999
PubMed

Insights

Long-term oral anticoagulation effectively prevents strokes in atrial fibrillation (AF) patients and after myocardial infarction. Optimal treatment targets an International Normalized Ratio (INR) of 2.0-3.0, with higher intensities posing risks.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) is a major risk factor for stroke.
  • Cerebral ischemia and myocardial infarction necessitate preventative strategies.
  • Oral anticoagulation is a cornerstone therapy in managing these conditions.

Purpose of the Study:

  • To review the efficacy of long-term oral anticoagulant therapy for stroke prevention.
  • To define optimal therapeutic ranges for anticoagulation intensity.
  • To assess the risks associated with different anticoagulation intensities.

Main Methods:

  • Literature review of studies on oral anticoagulation in stroke prevention.
  • Analysis of treatment guidelines and clinical trial data.
  • Evaluation of International Normalized Ratio (INR) targets and outcomes.

Main Results:

  • Oral anticoagulation is the primary treatment for AF patients with vascular risk factors or recent cerebral ischemia.
  • The therapy significantly reduces stroke risk post-myocardial infarction.
  • An INR of 2.0-3.0 is identified as the optimal target range for stroke prevention.

Conclusions:

  • Long-term oral anticoagulation is valuable for stroke prevention in specific patient groups.
  • Therapeutic intensity is crucial; higher INR levels (3.0-4.5) may be hazardous in certain arterial stroke cases.
  • Further research is needed to establish optimal lower-intensity anticoagulation for transient ischemic attack (TIA) or minor arterial stroke.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...